Trial reportClinical journal of the American Society of Nephrology : CJASN2019
High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy.
Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02199145 (Indication and Response to Immunosuppressive Treatment in Membranous Nephropathy), which is not on this map. Cited by 88 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Indication and Response to Immunosuppressive Treatment in Membranous Nephropathy : Role of Anti-mouse PLA2R1 ELISA
Who cites it
88 citing papers in PubMed, 3 syntheses or guidelines pooled it, 128 citations in OpenAlex.
- Efficacy of low or heavy rituximab‑based protocols and comparison with seven regimens in idiopathic membranous nephropathy: a systematic review and network meta-analysis.International urology and nephrology · 2023Pooled it
- Rituximab for the treatment of idiopathic membranous nephropathy with nephrotic syndrome: a systematic review and meta-analysisTurkish journal of medical sciences · 2021Pooled it
- Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis.Medicine · 2020Pooled it
- Efficacy and safety of Mahuang Fuzi and Shenzhuo Decoction for treatment of primary membranous nephropathy: a multicenter prospective trial.Renal failure · 2024Trial
- MHC class II and PLA2R investigating the epitope presentation deficits driving antibody production in membranous nephropathy.International urology and nephrology · 2026Review
- Response to the Letter to the Editor Entitled "Critical Reappraisal of Obinutuzumab Randomized Trials in Membranous Nephropathy".Kidney international reports · 2026Article
- Retrospective study of treatment effectiveness and remission predictors of obinutuzumab in primary membranous nephropathy.BMC nephrology · 2026Article
- Research Advances in Rituximab-Resistant Membranous Nephropathy.Kidney medicine · 2026Review
- A retrospective study of the efficacy and safety of rituximab biosimilar for the treatment of membranous nephropathy.BMC pharmacology & toxicology · 2026Article
- Obinutuzumab versus rituximab in refractory membranous nephropathy: a single-center retrospective cohort study.BMC nephrology · 2026Article
- Rituximab with low-dose glucocorticoids for treating refractory membranous nephropathy: a prospective single-center cohort study.Frontiers in pharmacology · 2026Article
- Treatment strategies for rituximab-resistant primary membranous nephropathy: from resistance mechanisms to emerging therapies.Frontiers in immunology · 2026Review
- Comparison of the efficacy of low, moderate and standard doses of rituximab in the treatment of membranous nephropathy.Frontiers in medicine · 2026Article
- Combination of B-cell-guided rituximab and low-dose tacrolimus for primary membranous nephropathy: a retrospective cohort study.Frontiers in medicine · 2026Article
- Optimized RTX strategy plus structured glucocorticoid tapering for primary membranous nephropathy: a multicenter propensity score-matched cohort study.Frontiers in molecular biosciences · 2026Article
- INPP5D/SHIP1-mediated immunometabolic remodeling of renal monocytes in idiopathic membranous nephropathy.Frontiers in immunology · 2026Article
- Contemporary review of primary membranous nephropathy.Frontiers in immunology · 2026Review
- First-line and Second-line Therapy of Zuberitamab in Idiopathic Membranous Nephropathy: A Single-center Retrospective Study.Kidney medicine · 2026Article
- Pharmacokinetic profiling of rituximab in glomerular diseases: key determinants and implications for personalized therapy.Frontiers in pharmacology · 2026Review
- Anti-PLA2R antibody levels and clinical risk factors for predicting relapse in primary membranous nephropathy.Frontiers in immunology · 2026Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
13 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesDifferent rituximab protocols are used to treat membranous nephropathy. We compared two rituximab protocols in patients with membranous nephropathy. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Twenty-eight participants from the NICE cohort received two infusions of 1-g rituximab at 2-week intervals, whereas 27 participants from the Prospective Randomized Multicentric Open Label Study to Evaluate Rituximab Treatment for Membranous Nephropathy (GEMRITUX) cohort received two infusions of 375 mg/m
resultsRemissions occurred in 18 (64%) versus eight (30%) from the NICE and GEMRITUX cohort (
conclusionsOur work suggests that higher dose rituximab protocol is more effective on depletion of B-cells and lack of epitope spreading is associated with remission of membranous nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.